A new drug being trialled for treating breast cancer and diabetes has been shown to ‘melt away’ the fat inside arteries that can cause heart attacks and strokes.
Researchers from the University of Aberdeen, using pre-clinical mouse models, showed that just a single dose of the drug (Trodusquemine) completely reversed the effects of a disease that causes a host of heart problems.
Atherosclerosis is the build-up of fatty material inside the arteries.
Over time this fatty material can grow bigger until your arteries become so narrow that not enough blood can pass through.
Atherosclerosis is the condition that causes most heart attacks and strokes.
In pre-clinical tests, mice with set-in atherosclerosis, mimicking what happens in humans, had less fatty plaques in their arteries whether they had regular doses over time or just a single dose of Trodusquemine.
The drug works by stopping an enzyme called PTP1B, which is normally increased in people with obesity or diabetes and conditions involving prolonged inflammation such as sepsis, inflamed diabetic foot ulcers and allergic lung inflammation. The researchers found that it also stimulated the action of another protein (AMPK), which effectively mimics exercise and reduces chronic inflammation.
It has already been shown to be effective with diabetes and breast cancer patients but this is the first time the drug has been shown to have benefits for long-term cardiovascular disease.
The £236,000 study was funded by the British Heart Foundation.
Professor Mirela Delibegovic and Dr Dawn Thompson from the University of Aberdeen’s Institute of Medical Sciences who led the study said: “All humans have some level of atherosclerosis. As you age you start to develop these fatty streaks inside your arteries. It is a big problem for people who are overweight or have underlying cardiovascular conditions.”
“Trodusquemine has already been trialled for treatment of diabetes and breast cancer but this is the first time it has been used in models of atherosclerosis.
“These have only been tested at pre-clinical level, in mice, so far but the results were quite impressive and showed that just a single dose of this drug seemed to completely reverse the effects of arthrosclerosis.
“The next step is to test the ability of this drug to improve outcomes in human patients with developed atherosclerosis and cardiovascular disease”.
Learn more: Drug ‘melts away’ fat inside arteries
The Latest on: Atherosclerosis
[google_news title=”” keyword=”atherosclerosis ” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Editorial: Novel Strategies for the Prevention and Treatment of Foam Cell Formation and Atherosclerosison November 18, 2023 at 7:45 am
The most common cause of CVD is atherosclerosis, a condition in which imbalances in lipid metabolism and a maladaptive immune response drive the formation of plaques in the artery wall, which can ...
- Drinking beer reduces heart diseaseon November 18, 2023 at 12:49 am
Researchers have revealed that traditional beers such as ale and stout can cut heart disease risk by mopping up harmful chemicals ...
- Role of Endothelial Dysfunction in Atherosclerosison November 13, 2023 at 4:00 pm
From the Hyperlipidemia and Atherosclerosis Research Group/Groupe de recherche sur les hyperlipidémies et l’athérosclérose, Clinical Research Institute of Montreal/Institut de recherches cliniques de ...
- Vascular Proliferation and Atherosclerosis: New Perspectives and Therapeutic Strategieson November 12, 2023 at 3:59 pm
In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...
- Atherosclerosis: RNA fragment creates prospect for new therapieson November 7, 2023 at 6:14 pm
Researchers have demonstrated the specific role microRNA plays in atherosclerosis -- and how it manages to intervene in this signaling pathway.
- MicroRNA Could Create Starting Point for New Atherosclerosis Therapyon November 5, 2023 at 4:00 pm
Atherosclerosis is considered a frequent cause of cardiovascular diseases and strokes. Despite medical progress, case numbers are constantly rising. Targeted new therapeutic approaches are therefore ...
- Atherosclerosis Drugs Market to be Worth US$ 62.8 Billion by 2033: Fact.MR Reporton November 5, 2023 at 2:00 pm
The rise in the availability of Novel Atherosclerosis drugs in European countries is expected to offer lucrative opportunities in coming yearsRockville, Nov. 05, 2023 (GLOBE NEWSWIRE) -- As per ...
- Olpasiran by Amgen for Atherosclerosis: Likelihood of Approvalon November 2, 2023 at 5:00 pm
Olpasiran is under clinical development by Amgen and currently in Phase III for Atherosclerosis. According to GlobalData, Phase III drugs for Atherosclerosis have a 24% phase transition success rate ...
- PTSD symptoms linked to higher carotid atherosclerosis in womenon November 2, 2023 at 5:00 pm
For midlife women, posttraumatic stress disorder (PTSD) symptoms are associated with higher carotid atherosclerosis and with greater brain small vessel disease and poorer cognitive performance among ...
- Study analyzes recent global and national trends of atherosclerosison November 1, 2023 at 5:00 pm
Atherosclerosis, which is characterized by a gradual build-up of plaque in the walls of arteries, is a serious cardiovascular condition that can result in ischemic heart disease (IHD), ischemic ...
via Google News and Bing News